Olmesartan

Top drugs and pharmaceutical companies of 2019 by revenues

Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-

Teva to sell assets to reduce debt, lay-off 7,000 workers; Shkreli awaits sentence

This week in Phispers, we look at the growing troubles at Teva. The company plans to divest non-core

The Next Generic Attack: Brilinta® (Ticagrelor), Xarelto® (Rivaroxaban), Tradjenta® (Linagliptin) and…

With almost 30,000 Drug Master Files (DMFs) submitted to the FDA, reviewing the filings of only the